AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Cidara Therapeutics Inc (NASDAQ:CDTX)
20.655 USD
-0.655 3.074%| Previous Close (in USD) | 21.31 |
|---|---|
| Change | -0.655 3.074% |
| 52 W H/L (in USD) | 24.400/10.004 |
| EBITDA (in USD) | -30.107M |
| PE Ratio | -- |
| Volume | 131940 |
| Diluted Eps TTM | -23.90 |
| Total Assets (in USD) | 68.53M |
|---|---|
| Total Liabilities (in USD) | 76.74M |
| Revenue TTM (in USD) | 53.87M |
| Cash (in USD) | 35.778M |
| Market Cap (in USD) | 246.235 M |
| Revenue Per Share TTM | 11.875 |
| Gross Profit TTM (in USD) | -11.232M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Cidara Therapeutics Inc
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
Employees: 69
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Jeffrey L. Stein Ph.D. | Pres, CEO & Exec. Director | 1955 |
| 2. | Dr. Taylor Sandison | Chief Medical Officer | 1972 |
| 3. | Dr. Les Tari Ph.D. | Chief Scientific Officer | NA |
| 4. | Dr. Kevin M. Forrest Ph.D. | Founder and Chief Strategy Officer | 1977 |
| 5. | Dr. Preetam Shah M.B.A., Ph.D. | CFO, Chief Bus. Officer & Principal Accounting Officer | 1973 |
| 6. | Mr. Shane M. Ward | COO & Chief Legal Officer | 1975 |
| 7. | Ms. Allison Lewis CCP, SPHR | VP of HR | NA |
| 8. | Mr. James M. Balkovec | Sr. VP of Research | NA |
| 9. | Ms. Laura A. Navalta | Sr. VP of Clinical Operations | NA |
| 10. | Ms. Carol Waldo | Sr. VP of Regulatory Affairs & Quality Assurance | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.365 0.493% | 73.84 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-1.320 1.776% | 73 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-9.585 2.138% | 451.26 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-3.910 0.761% | 521.05 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -29.527M | -42.467M | -72.111M | -41.092M | -59.016M |
| Minority Interest | - | - | - | - | - |
| Net Income | -29.799M | -43.909M | -72.373M | -40.085M | -59.016M |
| Selling General Administrative | 18.486M | 18.74M | 15.899M | 16.238M | 14.143M |
| Gross Profit | 64.288M | 49.572M | 12.067M | 20.915M | -49.142M |
| Reconciled Depreciation | 1.225M | -1.23M | 0.286M | 0.328M | 0.523M |
| Ebit | -30.943M | -41.025M | -71.849M | -41.724M | -67.659M |
| Ebitda | -29.718M | -42.255M | -71.62M | -42.135M | -67.136M |
| Depreciation And Amortization | 1.225M | -1.23M | 0.229M | -0.411M | 0.523M |
| Operating Income | -29.718M | -42.255M | -71.849M | -41.724M | -63.285M |
| Other Operating Expenses | 94.006M | 91.827M | 83.916M | 62.639M | 63.285M |
| Interest Expense | 0.191M | 0.212M | -0.262M | 0.221M | 0.629M |
| Tax Provision | 0.272M | - | - | - | - |
| Interest Income | - | - | - | 0.632M | - |
| Net Interest Income | 0.191M | -0.212M | -0.262M | 0.221M | 0.629M |
| Income Tax Expense | 0.272M | 1.442M | 0.262M | -1.007M | 4.269M |
| Total Revenue | 64.288M | 49.572M | 12.067M | 20.915M | 0M |
| Total Operating Expenses | 94.006M | 91.827M | 83.916M | 62.639M | 63.285M |
| Cost Of Revenue | - | - | - | 46.401M | 49.142M |
| Total Other Income Expense Net | 0.191M | -0.212M | -0.262M | 0.632M | 3.64M |
| Net Income From Continuing Ops | -29.799M | -42.467M | -72.111M | -41.092M | -59.016M |
| Net Income Applicable To Common Shares | -29.799M | -42.467M | -74.873M | -41.092M | -69.345M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 68.53M | 47.593M | 75.325M | 60.424M | 68.976M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 2.734M | 6.53M | 6.662M | 10.104M | 5.546M |
| Total Liab | 76.74M | 50.497M | 53.752M | 49.709M | 31.141M |
| Total Stockholder Equity | -8.21M | -2.904M | 21.573M | 10.715M | 37.835M |
| Other Current Liab | 37.251M | 12.594M | 15.057M | 12.169M | 7.726M |
| Common Stock | 0.009M | 0.007M | 0.007M | 0.004M | 0.003M |
| Capital Stock | 0.009M | 0.007M | 0.007M | 0.004M | 0.003M |
| Retained Earnings | -441.431M | -406.966M | -377.167M | -334.7M | -259.827M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | 1.084M | 2.891M | 1.101M |
| Cash | 35.778M | 32.731M | 62.273M | 35.912M | 60.268M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 67.418M | 29.972M | 34.017M | 38.564M | 30.199M |
| Current Deferred Revenue | 25.095M | 14.614M | 13.92M | 13.865M | 9.803M |
| Net Debt | -30.901M | -31.414M | -57.212M | -27.95M | -48.543M |
| Short Term Debt | 1.3M | 1.317M | 3.739M | 7.962M | 10.783M |
| Short Long Term Debt | - | - | 2.591M | 7.023M | 9.965M |
| Short Long Term Debt Total | 4.877M | 1.317M | 5.061M | 7.962M | 11.725M |
| Other Stockholder Equity | 433.212M | 404.055M | 398.733M | 345.411M | 297.659M |
| Property Plant Equipment | - | 0.222M | 2.543M | 0.342M | 0.429M |
| Total Current Assets | 60.855M | 45.094M | 71.698M | 57.191M | 65.814M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | 16.246M | 5.833M | 5.356M | 11.175M | 5.546M |
| Long Term Debt | - | - | - | - | - |
| Inventory | 6.097M | - | -2.593M | - | -5.546M |
| Accounts Payable | 3.772M | 1.447M | 1.301M | 4.568M | 1.887M |
| Accumulated Other Comprehensive Income | - | - | - | - | -2.842M |
| Non Currrent Assets Other | 1.048M | 1.072M | 1.084M | 2.023M | 1.101M |
| Non Current Assets Total | 7.675M | 2.499M | 3.627M | 3.233M | 3.162M |
| Capital Lease Obligations | 4.877M | 1.317M | 2.47M | 0.939M | 1.76M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -0.118M | -0.041M | -0.186M | -0.035M | 14.478M |
| Total Cashflows From Investing Activities | -0.118M | -0.041M | -0.186M | -0.035M | 14.301M |
| Total Cash From Financing Activities | -0.951M | 44.597M | 37.278M | 14.273M | 56.153M |
| Net Income | -29.799M | -42.467M | -72.111M | -41.092M | -59.016M |
| Change In Cash | -29.542M | 19.324M | -17.319M | -14.294M | 13.749M |
| Begin Period Cash Flow | 62.273M | 42.949M | 60.268M | 74.562M | 60.813M |
| End Period Cash Flow | 32.731M | 62.273M | 42.949M | 60.268M | 74.562M |
| Total Cash From Operating Activities | -28.473M | -25.232M | -54.411M | -28.532M | -56.705M |
| Depreciation | 1.225M | -1.23M | 0.229M | 0.375M | 0.523M |
| Other Cashflows From Investing Activities | - | - | - | - | 14.478M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | 1.093M | -6.591M | - | - |
| Sale Purchase Of Stock | 1.642M | - | 11.055M | 9.008M | 6.644M |
| Other Cashflows From Financing Activities | -0.72M | 0.006M | 0.014M | -9.032M | 49.713M |
| Capital Expenditures | 0.118M | 0.041M | 0.186M | 0.035M | 0.177M |
| Change In Working Capital | -3.432M | 14.436M | 13.36M | 7.487M | -0.399M |
| Other Non Cash Items | 0.001M | 0.015M | 0.021M | 0.036M | 0.086M |
| Free Cash Flow | -28.591M | -25.273M | -54.597M | -28.567M | -56.882M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vifag 2002 SICAV | 8 months ago | 24389 |
| 2. | Sun Life CC&L Group Income & Growth Seg | 1 year ago | 17529 |
| 3. | BlackRock Extended Equity Market K | 8 months ago | 10915 |
| 4. | iShares Micro-Cap ETF | 6 months ago | 9874 |
| 5. | Fidelity Total Market Index | 7 months ago | 9297 |
| 6. | Northern Small Cap Core I | 8 months ago | 7600 |
| 7. | Fidelity Series Total Market Index | 7 months ago | 6512 |
| 8. | NT Ext Equity Mkt Idx Fd - NL | 8 months ago | 4397 |
| 9. | NT Quality Small Cap Core | 8 months ago | 3838 |
| 10. | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 8 months ago | 3543 |
| 11. | Spartan Extended Market Index Pool E | 7 months ago | 3517 |
| 12. | NT Ext Equity Mkt Idx Fd - L | 8 months ago | 3354 |
| 13. | Vanguard Total Stock Mkt Idx Inv | 7 months ago | 121550 |
| 14. | Vanguard Institutional Extnd Mkt Idx Tr | 7 months ago | 52387 |
| 15. | A4Investments SICAV SIF ACCI IlanaA2EURH | 6 months ago | 35500 |
| 16. | Fidelity Extended Market Index | 7 months ago | 27328 |
| 17. | Northern Trust Extended Eq Market Idx | 8 months ago | 3354 |
| 18. | Fidelity Nasdaq Composite Index | 7 months ago | 3323 |
| 19. | Vanguard Balanced Index Inv | 7 months ago | 2966 |
| 20. | Vanguard Instl Ttl Stk Mkt Idx InstlPls | 7 months ago | 2739 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | RA Capital Management, LLC | 8 months ago | 703080 |
| 2. | Bain Capital Life Sciences Investors, LLC | 8 months ago | 703080 |
| 3. | Bvf Inc | 8 months ago | 703065 |
| 4. | Monashee Investment Management LLC | 8 months ago | 369099 |
| 5. | Checkpoint Capital LP | 8 months ago | 182426 |
| 6. | Vanguard Group Inc | 8 months ago | 180535 |
| 7. | Renaissance Technologies Corp | 8 months ago | 97817 |
| 8. | Alethea Capital Management, LLC | 8 months ago | 79908 |
| 9. | 5AM Venture Management, LLC | 8 months ago | 56725 |
| 10. | Geode Capital Management, LLC | 8 months ago | 52898 |
| 11. | BlackRock Inc | 11 months ago | 48512 |
| 12. | Adage Capital Partners Gp LLC | 8 months ago | 42755 |
| 13. | Northern Trust Corp | 8 months ago | 31787 |
| 14. | Schonfeld Strategic Advisors LLC | 8 months ago | 19500 |
| 15. | Millennium Management LLC | 8 months ago | 13919 |
| 16. | State Street Corp | 8 months ago | 13576 |
| 17. | U.S. Bancorp | 11 months ago | 13103 |
| 18. | UBS Group AG | 8 months ago | 5877 |
| 19. | Tower Research Capital LLC | 8 months ago | 1115 |
| 20. | Acadian Asset Management LLC | 8 months ago | 855 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...